CASI Pharma (CASI) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
CASI Pharmaceuticals (CASI) PT Raised to $6 at Oppenheimer
August 13, 2021 9:21 AM EDTOppenheimer analyst Leland Gershell raised the price target on CASI Pharmaceuticals (NASDAQ: CASI) to $6.00 (from $5.00) while maintaining an Outperform rating.
The analyst commented, "CASI reported another quarter of solid Evomela growth, posting 2Q21 revenue of $7.1M (+25% Q/Q, +173% Y/Y) vs. our $6.2M... More
